Hint mode is switched on Switch off
For swift navigation between sections

TetraLogic
LEI 549300X6IO859O0VG962

PDF download

Choose all Reset all
Download Cancel
Organization name
TetraLogic Pharmaceuticals Corporation
Country name
USA
Country of registration
USA
Industry
Miscellaneous Healthcare: Products and Services
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. In April 2014,Tetralogic Pharmaceuticals Corp acquired the entire share capital of Shape Pharmaceutical Inc.

Awards

Documentation

IFRS/US GAAP reports

2016
I q eng
II q eng
III q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300X6IO859O0VG962
  • CIK
    0001361248
Registration is required to get access.